Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1New Perspectives on Antimicrobial Agents: FosmanogepixClinical Trial · 2026 · 3 citations
2Activity of manogepix and comparator antifungal agents against uncommon filamentous fungal isolates collected in a global surveillance programLate-Phase Clinical Trial · 2026
3Manogepix demonstrates potent <i>in vitro</i> activity against <i>Aspergillus, Coccidioides</i> , <i>Scopulariopsis/Microascus, Rasamsonia</i> , and <i>Purpureocillium</i> species, including strains with <i>in vitro</i> resistance to other antifungalsIn Vitro Study · 2026 · 2 citations
4Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris : Results from a Phase 2 TrialHuman Clinical Trial · 2023 · 92 citations
5Clinical Efficacy and Safety of Fosmanogepix in Patients with Invasive and Refractory Fungal Infections: A Systematic ReviewSystematic Review · 2026
6P-1195. Activity of manogepix against surveillance yeast isolates collected from the United States in 2023Late-Phase Clinical Trial · 2026
7147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept TrialHuman Clinical Trial · 2020 · 17 citations
8Pharmacokinetics, safety, and tolerability of fosmanogepix IV to oral switch and multiple IV doses in healthy participants2024 · 12 citations
9Epstein-Barr Virus-Associated Dysautonomia With a Postural Orthostatic Tachycardia Syndrome Phenotype: A Case ReportCureus · 2026
10Delayed Stanford Type A Aortic Dissection Following Transcatheter Aortic Valve Implantation in a Patient With Pre-existing Ascending Aortic DilatationCureus · 2026

More from Cureus

More from University of Szeged